The Blood Products Advisory Committee (BPAC) reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility, and advises the Commissioner of Food and Drugs of its findings.
The Committee shall consist of a core of 17 voting members including the Chair. The core of the voting members may include one technically qualified member who is identified with consumer interest. In addition to the voting members, the Committee may include one nonvoting member who is identified with industry interest.
- FDA Advisory Committee Information Line
- (301-443-0572 in the Washington DC area)
Please call the Information Line for up-to-date information on this meeting.